Linked Life Data

18938112

Source:http://linkedlifedata.com/resource/pubmed/id/18938112

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18938112rdf:typepubmed:Citationlld:pubmed
pubmed-article:18938112lifeskim:mentionsumls-concept:C0282554lld:lifeskim
pubmed-article:18938112lifeskim:mentionsumls-concept:C0535298lld:lifeskim
pubmed-article:18938112lifeskim:mentionsumls-concept:C0009447lld:lifeskim
pubmed-article:18938112lifeskim:mentionsumls-concept:C1439296lld:lifeskim
pubmed-article:18938112lifeskim:mentionsumls-concept:C0021376lld:lifeskim
pubmed-article:18938112lifeskim:mentionsumls-concept:C1332814lld:lifeskim
pubmed-article:18938112lifeskim:mentionsumls-concept:C1880177lld:lifeskim
pubmed-article:18938112pubmed:issue2lld:pubmed
pubmed-article:18938112pubmed:dateCreated2009-1-5lld:pubmed
pubmed-article:18938112pubmed:abstractTextCommon variable immunodeficiency (CVID) is a heterogeneous syndrome characterized by defective immunoglobulin production and high frequency of bacterial infections, autoimmunity and manifestations of chronic inflammation. The chemokine Fractalkine (CX3CL1) and its receptor CX3CR1 is suggested to play an important role in the pathogenesis of several inflammatory disorders. We hypothesized that enhanced CX3CL1/CX3CR1 interaction could be involved in the chronic inflammation characterising subgroups of CVID. CVID patients were characterized by raised plasma levels of CX3CLl and enhanced expression of its corresponding receptor CX3CR1 on CD4(+) and CD8(+) T cells, including both CD45RA(+) and CD45RA(-) subsets. CX3CR1 expression was particularly enhanced in patients characterized by chronic inflammation in vivo. The high expression of the receptor in CVID patients was accompanied by enhanced chemotactic, adhesive, and other inflammatory cell responses to stimulation with CX3CL1. Our findings suggest that increased CX3CL1/CX3CR1 interaction could contribute to the inflammatory phenotype seen in subgroups of CVID patients.lld:pubmed
pubmed-article:18938112pubmed:languageenglld:pubmed
pubmed-article:18938112pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18938112pubmed:citationSubsetIMlld:pubmed
pubmed-article:18938112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18938112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18938112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18938112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18938112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18938112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18938112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18938112pubmed:statusMEDLINElld:pubmed
pubmed-article:18938112pubmed:monthFeblld:pubmed
pubmed-article:18938112pubmed:issn1521-7035lld:pubmed
pubmed-article:18938112pubmed:authorpubmed-author:AukrustPålPlld:pubmed
pubmed-article:18938112pubmed:authorpubmed-author:FrølandStig...lld:pubmed
pubmed-article:18938112pubmed:authorpubmed-author:UelandThorTlld:pubmed
pubmed-article:18938112pubmed:authorpubmed-author:YndestadArneAlld:pubmed
pubmed-article:18938112pubmed:authorpubmed-author:DamåsJan KJKlld:pubmed
pubmed-article:18938112pubmed:authorpubmed-author:HolmAre MAMlld:pubmed
pubmed-article:18938112pubmed:authorpubmed-author:BjerkeliVigdi...lld:pubmed
pubmed-article:18938112pubmed:authorpubmed-author:BeiskeKlausKlld:pubmed
pubmed-article:18938112pubmed:authorpubmed-author:FevangBørreBlld:pubmed
pubmed-article:18938112pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18938112pubmed:volume130lld:pubmed
pubmed-article:18938112pubmed:ownerNLMlld:pubmed
pubmed-article:18938112pubmed:authorsCompleteYlld:pubmed
pubmed-article:18938112pubmed:pagination151-61lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:meshHeadingpubmed-meshheading:18938112...lld:pubmed
pubmed-article:18938112pubmed:year2009lld:pubmed
pubmed-article:18938112pubmed:articleTitleChemokines and common variable immunodeficiency; possible contribution of the fractalkine system (CX3CL1/CX3CR1) to chronic inflammation.lld:pubmed
pubmed-article:18938112pubmed:affiliationResearch Institute for Internal Medicine, Rikshospitalet, University of Oslo, N-0027 Oslo, Norway. Borre.Fevang@medisin.uio.nolld:pubmed
pubmed-article:18938112pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18938112pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:1524entrezgene:pubmedpubmed-article:18938112lld:entrezgene
entrez-gene:6376entrezgene:pubmedpubmed-article:18938112lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18938112lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18938112lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18938112lld:pubmed